$LMNL News
Last published 3y ago
- 3y agoLMNLLIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously
- 3y agoLMNLLIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of
- 3y agoLMNLLIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the
- 3y agoLMNLLIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 12, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule
- 3y agoLMNLLIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LPPR NewswireLAVAL, QC and CAMBRIDGE, England, Aug. 16, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice
- 3y agoLMNLLiminal BioSciences Reports Second Quarter Financial Results 2023PR NewswireProvided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist programClosed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide cash runway into
- 3y agoLMNLLiminal BioSciences Announces Arrangement Agreement with Structured Alpha LPPR NewswireLiminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO, July 12, 2023 /PRNewswire/ - Liminal BioSciences Inc.
- 3y agoLMNLLiminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of ShareholdersPR NewswireLAVAL, QC and CAMBRIDGE, England, June 5, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of
- 3y agoLMNLLiminal BioSciences Provides R&D UpdatePR NewswireLMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA) enabling preclinical studies
- 3y agoLMNLLiminal BioSciences Reports First Quarter Financial Results 2023PR NewswireGPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide cash runway into early
- 3y agoLMNLThe Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction ProposalPR NewswireLAVAL, QC and CAMBRIDGE, England, May 8, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has already
- 3y agoLMNLLiminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction ProposalPR NewswireLAVAL, QC and CAMBRIDGE, England, April 5, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), confirms that following close of markets on April 4, 2023, the
- 3y agoLMNLLiminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial ResultsPR NewswireCTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40
- 3y agoLMNLLiminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023PR NewswireLAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter
- 3y agoLMNLLiminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price RequirementPR NewswireLAVAL, QC, Feb. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC
- 3y agoLMNLLiminal BioSciences Announces Reverse Stock SplitPR NewswireLAVAL, QC and CAMBRIDGE, England, Jan. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and
- 3y agoLMNLLiminal BioSciences to Present at BIO CEO & Investor ConferencePR NewswireLAVAL, QC and CAMBRIDGE, England, Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at
- 3y agoLMNLLiminal BioSciences Announces Priorities For 2023PR NewswireClosed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024.Plans to divest its remaining non-core assets, to further extend runway.Nominated LMNL6511 as its GPR84
- 3y agoLMNLLiminal BioSciences Announces Holding of Special Meeting of ShareholdersPR NewswireLAVAL, QC and CAMBRIDGE, England, Nov. 25, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting
- 4y agoLMNLLiminal BioSciences Reports Third Quarter 2022 Financial Results and Business HighlightsPR Newswire$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million
- 4y agoLMNLLiminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022PR NewswireLAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter
- 4y agoLMNLLiminal BioSciences Announces Listing Transfer to Nasdaq Capital MarketPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 1, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock M
- 4y agoLMNLLiminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireLAVAL, QC and CAMBRIDGE, England, Aug. 29, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Limi
- 4y agoLMNLLiminal BioSciences Announces Termination of Legacy CDMO ContractPR NewswireTermination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND, Aug. 25, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NAS
- 4y agoLMNLLiminal BioSciences Reports Second Quarter 2022 Financial Results and Business HighlightsPR Newswire$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021
- 4y agoLMNLLiminal BioSciences Announces Discontinuation of Fezagepras DevelopmentPR NewswireLAVAL, QC and CAMBRIDGE, England, July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras.
- 4y agoLMNLLiminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of ShareholdersPR NewswireLAVAL, QC and CAMBRIDGE, England, June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6, 2
- 4y agoLMNLLiminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of FezageprasPR NewswireLAVAL, QC and CAMBRIDGE, England, May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD")
- 4y agoLMNLLiminal BioSciences Reports First Quarter 2022 Financial Results and Business HighlightsPR NewswirePlanned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascending Dose ("MAD") clinical trial of fezagepras Repa
- 4y agoLMNLLiminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022PR NewswireLAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021. Li
- 4y agoLMNLLiminal Biosciences to Present at Upcoming Investor ConferencesPR NewswireLAVAL, QC, and CAMBRIDGE, England, May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal
- 4y agoLMNLA Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate - NCT05349435ClinicalTrials.govSafety and tolerability, AUC, Cmax, Tmax
- 4y agoLMNLLiminal BioSciences Reports Fourth Quarter and Year End 2021 Financial ResultsPR NewswirePlanned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan and release of security on the Company's assets
- 4y agoLMNLLiminal BioSciences Provides Update on Its Lead Drug Candidate FezageprasPR NewswireAnalysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD") trial, commencing in Q2 2022, to compare fezag
- 4y agoLMNLLiminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementPR NewswireLAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifica
- 4y agoLMNLLiminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LPPR NewswireRepayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its secured assets, including Intellectual Property Im
- 4y agoLMNLLiminal BioSciences Announces Strategic Priorities For 2022PR NewswireLAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022.
- 4y agoLMNLLiminal BioSciences Reports Third Quarter 2021 Financial ResultsPR NewswireClosing of the Sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A Completion of the Clinical Phase of the Phase 1 Multi-A
- 5y agoLMNLLiminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics BusinessPR NewswireLAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics
- 5y agoLMNLLiminal BioSciences Announces Closing of Sale of Priority Review VoucherPR NewswireLAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Prio
- 5y agoLMNLLiminal BioSciences Reports Second Quarter 2021 Financial ResultsPR NewswireReceipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedrion Closing of the Sale of Plasma Collection
- 5y agoDAREDSKEGNOGLMNL+1Thinking about buying stock in Golden Nugget Online Gaming, Dare Bioscience, Liminal BioSciences, Windtree Therapeutics, or Daseke Inc?PR NewswireNEW YORK, Aug. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNOG, DARE, LMNL, WINT, and DSKE. T
- 5y agoLMNLLiminal BioSciences Announces Sale of Priority Review Voucher for USD105MPR NewswireLAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to
- 5y agoLMNLLiminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing FacilityPR NewswireLAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced dive
- 5y agoLMNLLiminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with KedrionPR NewswireLAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exercised its option to acquire the remainder of the Compa
- 5y agoBNGOCLOVLMNLMVIS+1Thinking about buying stock in BioNano Genomics, RA Medical Systems, Microvision, Liminal BioSciences, or Clover Health?PR NewswireNEW YORK, June 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNGO, RMED, MVIS, LMNL, and CLOV. T
- 5y agoLMNLLiminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)PR NewswireLAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually
- 5y agoLMNLLiminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)PR NewswireLAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh
- 5y agoLMNLLiminal BioSciences Provides an Update on Currently Planned Clinical Activities for FezageprasPR NewswireLAVAL, QC and CAMBRIDGE, England, May 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic ("PK") result
- 5y agoLMNLLiminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with KedrionPR NewswireLAVAL, QC and CAMBRIDGE, England, May 21, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced dive